Ochsner doctors weigh in on Pfizer COVID-19 vaccine for children 12 and up By Chandler Watkins | May 12, 2021 at 3:32 PM CDT - Updated May 12 at 3:33 PM
SHREVEPORT, La. (KSLA) - The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices voted to approve the use of Pfizerâs and BioNTechâs COVID-19 vaccine for kids as young as 12 years old.
This comes just days after the FDA announced it approved Pfizerâs and BioNTechâs request to allow their vaccines to be given to children on an emergency basis. The vaccine is already authorized for use in people 16 and older. It will be administered in adolescents in two doses, three weeks apart, the same regimen for those 16 and older, according to the FDA.
According to the Virginia Department of Health, the Pfizer vaccine could be approved for use in children aged 12 to 15 as early as next week, but The Virginia Research Center is getting ready to start a new study that would test the effectiveness of lower vaccine doses in kids below the age of 12.
May 05, 2021
The Louisiana Department of Health is reporting additional progress in reducing severe maternal morbidity among birthing persons who experience hemorrhage and severe hypertension in facilities that are part of the Louisiana Perinatal Quality Collaborative (LaPQC). The LaPQC’s final report on Reducing Maternal Morbidity, issued today, shows that severe maternal morbidity among hemorrhage was reduced by nearly 35% and severe maternal morbidity among hypertension was reduced by almost 12%.
The Reducing Maternal Morbidity Initiative was designed to reduce the occurrence of two recognized contributors to maternal morbidity and mortality: preventable hypertension and/or hemorrhage, while also reducing disparities in outcomes.
This data shows that Louisiana has made significant progress toward ensuring safe, equitable and dignified births for all birthing persons in Louisiana. The final report covers work that began in 2018 with the launch of the Louisiana Department of H
LDH reports improvements in maternal morbidity in La., but racial disparity remains (Source: pexels.com) By Rachael Thomas | May 5, 2021 at 12:02 PM CDT - Updated May 5 at 12:03 PM
BATON ROUGE, La. (KSLA) - The Louisiana Department of Health (LDH) released a report Wednesday, May 5 detailing progress in reducing severe maternal morbidity among those who experience hemorrhage and severe hypertension in facilities that are part of the Louisiana Perinatal Quality Collaborative (LaPQC), however, a racial disparity remains.
LaPQC’s report on Reducing Maternal Morbidity shows severe maternal morbidity among hemorrhage was reduced by almost 35% and severe maternal morbidity among severe hypertension was reduce by nearly 12%. The initiative was first launched to reduce the occurrence of these two contributors to maternal morbidity: preventable hypertension and/or hemorrhage, and to also reduce disparities in outcomes.